{"filing":{"accession_number":"0001213900-26-076411","cik":"0001713863","ticker":"RFL","company_name":"Rafael Holdings, Inc.","form":"8-K","filing_date":"2026-07-08","report_date":null,"primary_document":"ea0297442-8k_rafael.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1713863/000121390026076411/ea0297442-8k_rafael.htm"},"events":[{"id":16751,"run_id":14977,"accession_number":"0001213900-26-076411","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Rafael Holdings furnished an investor presentation under Item 7.01 (Regulation FD Disclosure) disclosing material clinical trial progress on its lead program Trappsol® Cyclo. The presentation details completion of the Phase 3 trial's last patient last visit (LPLV) in June 2026, completion of a pre-NDA meeting, and expected NDA submission and topline data in 2H 2026. This represents a significant operational and clinical milestone for a late-stage biotechnology company, affecting investor assessment of the registrant's path to potential regulatory approval and commercialization of its lead orphan drug candidate.","company_name":"Rafael Holdings, Inc.","ticker":"RFL","filing_date":"2026-07-08","form":"8-K","submitted_at":null,"items":[{"id":14938,"accession_number":"0001213900-26-076411","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Rafael Holdings furnished an investor presentation under Item 7.01 (Regulation FD Disclosure) disclosing material clinical trial progress on its lead program Trappsol® Cyclo. The presentation details completion of the Phase 3 trial's last patient last visit (LPLV) in June 2026, completion of a pre-NDA meeting, and expected NDA submission and topline data in 2H 2026. This represents a significant operational and clinical milestone for a late-stage biotechnology company, affecting investor assessment of the registrant's path to potential regulatory approval and commercialization of its lead orphan drug candidate.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-08T20:46:39.660283+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":14938,"accession_number":"0001213900-26-076411","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Rafael Holdings furnished an investor presentation under Item 7.01 (Regulation FD Disclosure) disclosing material clinical trial progress on its lead program Trappsol® Cyclo. The presentation details completion of the Phase 3 trial's last patient last visit (LPLV) in June 2026, completion of a pre-NDA meeting, and expected NDA submission and topline data in 2H 2026. This represents a significant operational and clinical milestone for a late-stage biotechnology company, affecting investor assessment of the registrant's path to potential regulatory approval and commercialization of its lead orphan drug candidate.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-08T20:46:39.660283+00:00","company_name":"Rafael Holdings, Inc.","ticker":"RFL","filing_date":"2026-07-08"}]}